Roche convinces NICE to make U-turn on MabThera
This article was originally published in Scrip
Executive Summary
NICE has issued draft guidance recommending Roche's MabThera (rituximab) as an option for treating some adults with a rare autoimmune condition, backtracking on previous draft guidance in which the institute was "not minded" to recommend the drug.